Innoviva, Inc. (INVA) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $21.73, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak).
Innoviva is a diversified biopharmaceutical company combining a respiratory royalty portfolio (RELVAR/BREO ELLIPTA and ANORO ELLIPTA licensed to GSK) with an acquired critical care/infectious disease platform (GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE) operated through... Read more
Hold if already holding. Not a fresh buy at $21.73, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Innoviva, Inc.
Latest news
- Innoviva (INVA) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength By Investing.com - Investing.com Australia — Investing.com Australia positive
- Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength - Investing.com — Investing.com positive
- [Form 4] Innoviva, Inc. Insider Trading Activity - Stock Titan — Stock Titan neutral
- Innoviva Stock Crosses 200-Day Moving Average - National Today — National Today neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyGSK10-K Item 1A: 'Currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK's ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $21.73, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $30.18 (+38.9%), stop $20.86 (−4.2%), A.R:R 5.8:1. Score 6.4/10, moderate confidence.
Take-profit target: $30.18 (+38.9% upside). Target $30.18 (+38.9%), stop $20.86 (−4.2%), A.R:R 5.8:1. Stop-loss: $20.86.
Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak); Negative momentum.
Innoviva, Inc. trades at a P/E of 3.5 (forward 9.9). TrendMatrix value score: 9.0/10. Verdict: Hold.
11 analysts cover INVA with a consensus score of 4.1/5. Average price target: $36.
What does Innoviva, Inc. do?Innoviva is a diversified biopharmaceutical company combining a respiratory royalty portfolio (RELVAR/BREO ELLIPTA and...
Innoviva is a diversified biopharmaceutical company combining a respiratory royalty portfolio (RELVAR/BREO ELLIPTA and ANORO ELLIPTA licensed to GSK) with an acquired critical care/infectious disease platform (GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE) operated through Innoviva Specialty Therapeutics. GSK royalty revenue represents the majority of near-term revenues; the company also holds a stake in Armata Pharmaceuticals and other strategic healthcare assets.